587 related articles for article (PubMed ID: 31352310)
1. Hyaluronic acid-functionalized gelatin hydrogels reveal extracellular matrix signals temper the efficacy of erlotinib against patient-derived glioblastoma specimens.
Pedron S; Wolter GL; Chen JE; Laken SE; Sarkaria JN; Harley BAC
Biomaterials; 2019 Oct; 219():119371. PubMed ID: 31352310
[TBL] [Abstract][Full Text] [Related]
2. Extracellular Hyaluronic Acid Influences the Efficacy of EGFR Tyrosine Kinase Inhibitors in a Biomaterial Model of Glioblastoma.
Pedron S; Hanselman JS; Schroeder MA; Sarkaria JN; Harley BAC
Adv Healthc Mater; 2017 Nov; 6(21):. PubMed ID: 28766870
[TBL] [Abstract][Full Text] [Related]
3. Brain-Mimetic 3D Culture Platforms Allow Investigation of Cooperative Effects of Extracellular Matrix Features on Therapeutic Resistance in Glioblastoma.
Xiao W; Zhang R; Sohrabi A; Ehsanipour A; Sun S; Liang J; Walthers CM; Ta L; Nathanson DA; Seidlits SK
Cancer Res; 2018 Mar; 78(5):1358-1370. PubMed ID: 29282221
[TBL] [Abstract][Full Text] [Related]
4. Crizotinib and erlotinib inhibits growth of c-Met
Goodwin CR; Rath P; Oyinlade O; Lopez H; Mughal S; Xia S; Li Y; Kaur H; Zhou X; Ahmed AK; Ho S; Olivi A; Lal B
Clin Neurol Neurosurg; 2018 Aug; 171():26-33. PubMed ID: 29803091
[TBL] [Abstract][Full Text] [Related]
5. Aptamer targeting EGFRvIII mutant hampers its constitutive autophosphorylation and affects migration, invasion and proliferation of glioblastoma cells.
Camorani S; Crescenzi E; Colecchia D; Carpentieri A; Amoresano A; Fedele M; Chiariello M; Cerchia L
Oncotarget; 2015 Nov; 6(35):37570-87. PubMed ID: 26461476
[TBL] [Abstract][Full Text] [Related]
6. Perivascular signals alter global gene expression profile of glioblastoma and response to temozolomide in a gelatin hydrogel.
Ngo MT; Harley BAC
Biomaterials; 2019 Apr; 198():122-134. PubMed ID: 29941152
[TBL] [Abstract][Full Text] [Related]
7. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells.
Vengoji R; Macha MA; Nimmakayala RK; Rachagani S; Siddiqui JA; Mallya K; Gorantla S; Jain M; Ponnusamy MP; Batra SK; Shonka N
J Exp Clin Cancer Res; 2019 Jun; 38(1):266. PubMed ID: 31215502
[TBL] [Abstract][Full Text] [Related]
8. JAK2/STAT3 targeted therapy suppresses tumor invasion via disruption of the EGFRvIII/JAK2/STAT3 axis and associated focal adhesion in EGFRvIII-expressing glioblastoma.
Zheng Q; Han L; Dong Y; Tian J; Huang W; Liu Z; Jia X; Jiang T; Zhang J; Li X; Kang C; Ren H
Neuro Oncol; 2014 Sep; 16(9):1229-43. PubMed ID: 24861878
[TBL] [Abstract][Full Text] [Related]
9. A human co-culture cell model incorporating microglia supports glioblastoma growth and migration, and confers resistance to cytotoxics.
Leite DM; Zvar Baskovic B; Civita P; Neto C; Gumbleton M; Pilkington GJ
FASEB J; 2020 Jan; 34(1):1710-1727. PubMed ID: 31914660
[TBL] [Abstract][Full Text] [Related]
10. Genomic profiling of a Hepatocyte growth factor-dependent signature for MET-targeted therapy in glioblastoma.
Johnson J; Ascierto ML; Mittal S; Newsome D; Kang L; Briggs M; Tanner K; Marincola FM; Berens ME; Vande Woude GF; Xie Q
J Transl Med; 2015 Sep; 13():306. PubMed ID: 26381735
[TBL] [Abstract][Full Text] [Related]
11. Erlotinib resistance in EGFR-amplified glioblastoma cells is associated with upregulation of EGFRvIII and PI3Kp110δ.
Schulte A; Liffers K; Kathagen A; Riethdorf S; Zapf S; Merlo A; Kolbe K; Westphal M; Lamszus K
Neuro Oncol; 2013 Oct; 15(10):1289-301. PubMed ID: 23877316
[TBL] [Abstract][Full Text] [Related]
12. Bioengineered 3D brain tumor model to elucidate the effects of matrix stiffness on glioblastoma cell behavior using PEG-based hydrogels.
Wang C; Tong X; Yang F
Mol Pharm; 2014 Jul; 11(7):2115-25. PubMed ID: 24712441
[TBL] [Abstract][Full Text] [Related]
13. Hypoxia activates enhanced invasive potential and endogenous hyaluronic acid production by glioblastoma cells.
Chen JE; Lumibao J; Blazek A; Gaskins HR; Harley B
Biomater Sci; 2018 Mar; 6(4):854-862. PubMed ID: 29485655
[TBL] [Abstract][Full Text] [Related]
14. Regulation of glioma cell phenotype in 3D matrices by hyaluronic acid.
Pedron S; Becka E; Harley BA
Biomaterials; 2013 Oct; 34(30):7408-17. PubMed ID: 23827186
[TBL] [Abstract][Full Text] [Related]
15. Histone Deacetylase Inhibitors Resensitize EGFR/EGFRvIII-Overexpressing, Erlotinib-Resistant Glioblastoma Cells to Tyrosine Kinase Inhibition.
Liffers K; Kolbe K; Westphal M; Lamszus K; Schulte A
Target Oncol; 2016 Feb; 11(1):29-40. PubMed ID: 26032687
[TBL] [Abstract][Full Text] [Related]
16. Resistance to EGF receptor inhibitors in glioblastoma mediated by phosphorylation of the PTEN tumor suppressor at tyrosine 240.
Fenton TR; Nathanson D; Ponte de Albuquerque C; Kuga D; Iwanami A; Dang J; Yang H; Tanaka K; Oba-Shinjo SM; Uno M; Inda MM; Wykosky J; Bachoo RM; James CD; DePinho RA; Vandenberg SR; Zhou H; Marie SK; Mischel PS; Cavenee WK; Furnari FB
Proc Natl Acad Sci U S A; 2012 Aug; 109(35):14164-9. PubMed ID: 22891331
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms of Resistance to EGFR Inhibition Reveal Metabolic Vulnerabilities in Human GBM.
McKinney A; Lindberg OR; Engler JR; Chen KY; Kumar A; Gong H; Lu KV; Simonds EF; Cloughesy TF; Liau LM; Prados M; Bollen AW; Berger MS; Shieh JTC; James CD; Nicolaides TP; Yong WH; Lai A; Hegi ME; Weiss WA; Phillips JJ
Mol Cancer Ther; 2019 Sep; 18(9):1565-1576. PubMed ID: 31270152
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of Rb and mTOR signaling associates with synergistic anticancer effect of palbociclib and erlotinib in glioblastoma cells.
Liu S; Tang Y; Yuan X; Yuan D; Liu J; Li B; Li Y
Invest New Drugs; 2018 Dec; 36(6):961-969. PubMed ID: 29508248
[TBL] [Abstract][Full Text] [Related]
19. The Combined Influence of Hydrogel Stiffness and Matrix-Bound Hyaluronic Acid Content on Glioblastoma Invasion.
Chen JE; Pedron S; Harley BAC
Macromol Biosci; 2017 Aug; 17(8):. PubMed ID: 28379642
[TBL] [Abstract][Full Text] [Related]
20. De-repression of PDGFRβ transcription promotes acquired resistance to EGFR tyrosine kinase inhibitors in glioblastoma patients.
Akhavan D; Pourzia AL; Nourian AA; Williams KJ; Nathanson D; Babic I; Villa GR; Tanaka K; Nael A; Yang H; Dang J; Vinters HV; Yong WH; Flagg M; Tamanoi F; Sasayama T; James CD; Kornblum HI; Cloughesy TF; Cavenee WK; Bensinger SJ; Mischel PS
Cancer Discov; 2013 May; 3(5):534-47. PubMed ID: 23533263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]